导师类型：博士生导师
单 位：05中药研究所
出生年月：1986年12月
专业职务：研究员
学 位：理学博士
毕业学校：新加坡国立大学
第一学科：中药学
第二学科：中药学
研究方向：中药活性分子的生物合成、合成生物学、中药药理
联系电话：17310119631
邮 箱：ccxu@icmm.ac.cn
邮 编：100700
联系地址：北京市东城区东直门内南小街16号
个人简介： 徐承超研究员，曾通过全球竞争，获得了国际“人类前沿科学计划”基金会的支持。2021年入选北京市科协青年人才托举工程，现参与负责国家重点研发计划合成生物学重点专项子任务1项，参与国家自然科学基金应急管理项目1项，是国家中医药传承创新团队项目“青蒿素传承创新团队”的核心成员。近期的主要成果以第一作者或共同第一作者或共同通讯作者在[b][i]Science, Nature Reviews Molecular Cell Biology, Nature Communications, ACS Central Science, Pharmacology & Therapeutics[/i][/b][b][i]，[/i][/b][b][i]Medicinal Research Reviews[/i][/b][b][i]，[/i][/b][b][i]Natural Product Reports[/i][/b]等国际权威期刊上发表。研究成果被[b][i]Science, Nature Chemical Biology, Nature Reviews Molecular Cell Biology[/i][/b]等权威期刊重点推荐报道。同时兼职药理学期刊（[b][i]Medicinal Research Reviews[/i][/b]）的客座编委和审稿人。
论文：
Identification of antimalarial targets of chloroquine by a combined deconvolution strategy of ABPP and MS-CETSA Military Medical Research (IF: 34.91) 2022/6/1
Discovery and repurposing of artemisinin Frontiers of Medicine (IF: 9.92) 2022/2/1
Study towards improving artemisinin-based combination therapies Natural Product Reports (IF: 15.11) 2021/7/1
Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity ACS Central Science (IF:18.72) 2017/7/1
Unpacking 'Artemisinin Resistance' Trends in Pharmacological Sciences (IF: 17.63) 2017/6/1
O-mannosylation: The other glycan player of ER quality control Seminars in Cell & Developmental Biology (IF: 7.49) 2015/5/1
Repeated evolution of cytochrome P450-mediated spiroketal steroid biosynthesis in plants Nature Communications (IF: 17.69) 2019/7/1
A Temporizing Solution to “Artemisinin Resistance” New England Journal of Medicine (IF: 176.07) 2019/5/1
Slp1-Emp65: A Guardian Factor that Protects Folding Polypeptides from Promiscuous Degradation Cell (IF: 66.84) 2017/10/1
Glycosylation-directed quality control of protein folding Nature Reviews Molecular Cell Biology (IF:113.91) 2015/12/1
Futile protein folding cycles in the ER are terminated by the unfolded protein O-mannosylation pathway Science (IF: 63.71) 2013/5/1
专著：
Target Profiling of an Anticancer Drug Curcumin by an in situ Chemical Proteomics Approach, Methods in Molecular Biology Humana, New York, NY
获奖：
Identification of antimalarial targets of chloroquine by a combined deconvolution strategy of ABPP and MS-CETSA Military Medical Research (IF: 34.91)
Discovery and repurposing of artemisinin Frontiers of Medicine (IF: 9.92)
Study towards improving artemisinin-based combination therapies Natural Product Reports (IF: 15.11)
Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity ACS Central Science (IF:18.72)
Unpacking 'Artemisinin Resistance' Trends in Pharmacological Sciences (IF: 17.63)
O-mannosylation: The other glycan player of ER quality control Seminars in Cell & Developmental Biology (IF: 7.49)
Repeated evolution of cytochrome P450-mediated spiroketal steroid biosynthesis in plants Nature Communications (IF: 17.69)
A Temporizing Solution to “Artemisinin Resistance” New England Journal of Medicine (IF: 176.07)
Slp1-Emp65: A Guardian Factor that Protects Folding Polypeptides from Promiscuous Degradation Cell (IF: 66.84)
Glycosylation-directed quality control of protein folding Nature Reviews Molecular Cell Biology (IF:113.91)
Futile protein folding cycles in the ER are terminated by the unfolded protein O-mannosylation pathway Science (IF: 63.71)
